Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cephalexin
Drug ID BADD_D00412
Description Cephalexin is the first of the first generation cephalosporins.[A179071,A179074] This antibiotic contains a beta lactam and a dihydrothiazide.[A179071] Cephalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis.[A179083,Label] Cephalexin was approved by the FDA on 4 January 1971.[L6547]
Indications and Usage For the treatment of respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes; otitis media due to Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, and Moraxella catarrhalis; skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes; bone infections caused by Staphylococcus aureus and/or Proteus mirabilis; genitourinary tract infections, including acute prostatitis, caused by Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae.
Marketing Status Prescription; Discontinued
ATC Code J01DB01
DrugBank ID DB00567
KEGG ID D00263
MeSH ID D002506
PubChem ID 27447
TTD Drug ID D0Z5EM
NDC Product Code 68180-441; 63629-9207; 63629-9200; 63187-205; 54348-555; 69778-930; 61919-606; 68071-5241; 67877-255; 0093-2240; 0143-9897; 65862-018; 68071-3186; 42291-209; 68071-4233; 53002-2182; 80425-0121; 62135-480; 63629-9199; 68071-4516; 53002-2180; 65862-019; 63629-9205; 63629-7740; 50268-151; 67296-0976; 68180-440; 61919-049; 67877-219; 53002-2181; 50090-4423; 69778-931; 70934-840; 60687-163; 50090-0070; 63629-8857; 68071-2249; 68071-5038; 65862-338; 68180-122; 71205-591; 60687-152; 72969-116; 43063-536; 63629-7927; 24979-155; 80425-0005; 50090-3111; 42582-211; 24979-154; 63629-9198; 50090-3057; 42582-212; 68788-7529; 0093-4175; 72287-310; 68071-1585; 50090-4795; 63187-046; 0143-9898; 67877-545; 68071-4355; 50090-5196; 70518-3362; 51655-028; 67296-0037; 63629-7743; 54348-560; 43063-634; 80425-0006; 50268-152; 68071-2246; 68071-5016; 63629-7605; 50090-3291; 66267-982; 68788-7938; 70518-2273; 63629-8856; 0093-3145; 68788-7796; 68180-121; 0093-3147; 50090-3252; 42291-208; 63629-9202; 69043-009; 69043-008; 68788-9539; 42708-070; 42708-017; 50090-3199; 53002-2260; 50090-2749; 63629-9204; 63629-9203; 50090-3202; 63629-8854; 63629-8858; 0093-4177; 63629-8981; 68788-7761; 55289-058; 70518-3066; 43063-678; 70934-040; 68788-9326; 68071-4406; 67877-544; 42708-145; 67877-254; 59651-230; 45865-428; 53002-2540; 70518-3378; 63629-8855; 63629-9206; 0143-9769; 70518-3059; 68071-5011; 43744-061; 63629-9201; 43063-497; 62135-481; 0093-2238; 0143-9770; 50090-0219; 42708-100; 50090-0220; 63629-8980; 68071-4434; 50090-3427; 68788-9713; 68788-9538; 71205-553; 55289-057; 70934-082; 67877-220; 68071-4429; 76420-052
Synonyms Cephalexin | Cefalexin | Cephalexin Hydrochloride | Cephalexin Monohydrochloride, Monohydrate | Cephalexin, (6R-(6alpha,7alpha(R*)))-Isomer | Cephalexin, (6R-(6alpha,7beta(S*)))-Isomer | Cephalexin, (6R-(6alpha,7beta))-Isomer | Cephalexin, Monosodium Salt | Cephalexin Monohydrochloride | Ceporexine | Palitrex | Cephalexin Monohydrate | Cephalexin Dihydride | Cephalexin Hemihydrate | 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- | Cephalexin, Monosodium Salt, (6R-(6alpha,7beta))-Isomer
Chemical Information
Molecular Formula C16H17N3O4S
CAS Registry Number 15686-71-2
SMILES CC1=C(N2C(C(C2=O)NC(=O)C(C3=CC=CC=C3)N)SC1)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Chills15.05.03.016; 08.01.09.0010.000155%
Cholecystitis acute09.03.01.0030.000077%Not Available
Cholestasis09.01.01.0010.000077%Not Available
Clostridium difficile colitis11.02.02.004; 07.19.01.0040.000030%Not Available
Colitis07.08.01.001--
Colitis ulcerative10.02.01.004; 07.08.01.0050.000271%Not Available
Confusional state17.02.03.005; 19.13.01.001--
Cough22.02.03.001--
Crohn's disease10.02.01.005; 07.08.01.0150.000232%Not Available
Death08.04.01.001--
Dehydration14.05.05.0010.000116%
Depression19.15.01.0010.000387%
Dermatitis23.03.04.002--Not Available
Dermatitis bullous23.03.01.0020.000077%
Diarrhoea07.02.01.0010.000813%
Disorientation19.13.01.002; 17.02.05.0150.000077%Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.0040.000387%
Drug eruption10.01.01.005; 08.01.06.015; 23.03.05.0010.000077%Not Available
Drug hypersensitivity10.01.01.0010.002246%Not Available
Dry skin23.03.03.0010.000155%
Dyspepsia07.01.02.0010.000077%
Dysphagia07.01.06.003--
Dyspnoea22.02.01.004; 02.01.03.0020.000349%
Eosinophilia01.02.04.001--
Epistaxis24.07.01.005; 22.04.03.0010.000232%
Erythema23.03.06.0010.000465%Not Available
Erythema multiforme23.03.01.003; 10.01.03.0150.000116%
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.0030.000077%
Fatigue08.01.01.002--
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 7 Pages